Chinese Wuhan Virus Thread

Tatvamasi

Well-Known member
Jan 5, 2018
669
569
India

whats up with this?
End of the day percentage is what matters to us. If you cant vaccinate 3-4 million per day end is not near unlike any of these comparing nations.
 
  • Agree
Reactions: jetray

Sathya

Senior member
Dec 2, 2017
2,180
1,196
India
Most of the states are recovering..
TN & NE states cases are still increasing.

In another 2 weeks all states will be recovering..

Guess in a month s time 2 nd wave will recede..
 
  • Like
Reactions: TARGET

RISING SUN

Senior member
Dec 3, 2017
8,615
4,397

The Wuhan Lab Leak Question: A Disused Chinese Mine Takes Center Stage​

DANAOSHAN, China—On the outskirts of a village deep in the mountains of southwest China, a lone surveillance camera peers down toward a disused copper mine smothered in dense bamboo. As night approaches, bats swoop overhead.


This is the subterranean home of the closest known virus on Earth to the one that causes Covid-19. It is also now a touchpoint for escalating calls for a more thorough probe into whether the pandemic could have stemmed from a Chinese laboratory.


In April 2012, six miners here fell sick with a mysterious illness after entering the mine to clear bat guano. Three of them died.


Chinese scientists from the Wuhan Institute of Virology were called in to investigate and, after taking samples from bats in the mine, identified several new coronaviruses.
 

STEPHEN COHEN

Senior member
Dec 4, 2017
6,384
3,914
And then, the third wave begins after a month or two.

Third wave will not happen

Vaccinations plus Natural Antibodies
Will prevent third wave

During The gap between First and Second wave all Natural Antibodies
Which had developed in people , were erased

But this time the difference is the number of vaccinated people

By 30 June , 260 million doses would have been given

For every 1 lab confirmed case , at least 5 are going undetected

Undetected cases also develop antibodies which is seen in seropositivity rates
 

Sathya

Senior member
Dec 2, 2017
2,180
1,196
India
Third wave will not happen

Vaccinations plus Natural Antibodies
Will prevent third wave

During The gap between First and Second wave all Natural Antibodies
Which had developed in people , were erased

But this time the difference is the number of vaccinated people

By 30 June , 260 million doses would have been given

For every 1 lab confirmed case , at least 5 are going undetected

Undetected cases also develop antibodies which is seen in seropositivity rates

I don't trust vaccine that much.
When infection itself doesn't give long term immunity.

We have to watch out for better vaccines in development.

Otherwise booster vaccines of old type after certain period of time..
 

STEPHEN COHEN

Senior member
Dec 4, 2017
6,384
3,914
I don't trust vaccine that much.
When infection itself doesn't give long term immunity.

We have to watch out for better vaccines in development.

Otherwise booster vaccines of old type after certain period of time..

My Relatives in US have been told that they will require 3rd dose of Pfizer Vaccine after 6 Months

Same thing will happen every where

Right now we Indians will struggle for even the First dose till July
 

RISING SUN

Senior member
Dec 3, 2017
8,615
4,397

Covid Antibody Cocktail, Used To Treat Donald Trump, Comes To India. It Costs...​

New Delhi:
Drug major Roche India on Monday announced the launch of its first batch of antibody cocktail against COVID-19 in India. The antibody cocktail -- Casirivimab and Imdevimab -- is priced at ₹ 59,750 per dose. Roche's antibody cocktail was given to former US President Donald Trump when he contracted COVID-19 last year.

In a statement, the company said: "Each of the 1,200 mg dose of the drug contains 600 mg of Casirivimab and 600 mg of Imdevimab. The price of each dose will be ₹ 59,750. The maximum retail price for the multi-dose pack will be ₹ 1,19,500. Notably, each pack can treat two patients."

The drug will be marketed in India by Cipla and the second batch will be made available by mid-June.

"The first batch of the antibody cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit two lakh patients as each of the one lakh packs that will be available in India offers treatment for two patients," according to a joint statement issued by Cipla and Roche.

The drug will be available through leading hospitals and COVID treatment centres.


The Central Drugs Standards Control Organisation (CDSCO) had recently provided an Emergency Use Authorisation (EUA) for the antibody cocktail in India. Earlier, it has also received a EUA in the US and several EU countries.

"Roche is deeply committed to supporting the ongoing efforts to combat the COVID-19 pandemic, mitigate the deadly second wave and save lives. We are optimistic that the availability of Antibody Cocktail (Casirivimab and Imdevimab) in India can help in minimizing hospitalization, ease the burden on healthcare systems and play a key role in the treatment of high-risk patients before their condition worsens," said V Simpson Emmanuel, Managing Director and CEO, Roche Pharma India.

The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and who are at high risk of developing severe COVID-19 disease and do not require oxygen.

39 Comments The cocktail drug has been shown to help these high-risk patients before their condition worsens, reducing the risk of hospitalisation and fatality by 70 per cent.
 

RISING SUN

Senior member
Dec 3, 2017
8,615
4,397

Pfizer ready with 5 cr doses of COVID vaccine for India in 2021; Moderna's single-dose likely next year​

New Delhi: Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 5 crore shots in 2021 itself but it wants significant regulatory relaxations including indemnification, sources said on Tuesday.


While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021, there are limited prospects of Johnson & Johnson exporting its jabs from the US to other countries in the near future, the sources privy to discussions added.


Two rounds of high-level meetings chaired by the Cabinet Secretary were held last week on the availability of vaccines in the global as well as domestic markets as it was felt that there is an urgent need to procure the jabs at a time the country is reeling under an unprecedented second wave of COVID-19 and a widening gap between supply and requirement.


Currently, the country is using two 'made-in India' jabs -- Covishield and Covaxin -- to inoculate its billion-plus population and has administered 20 crore doses since launching the world's largest vaccination drive in mid-January. A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present.

In the high-level meeting officials from the Ministry of External Affairs, NITI Aayog, Department of Biotechnology, Law Ministry and Health Ministry were present.


It was discussed that Moderna doesn't have surplus vaccines to share in 2021 and that it plans to launch its single-dose vaccine for the Indian market only in 2022, for which, they are in discussion with Cipla and other Indian companies, a source said.


It is learnt that Cipla has already evinced interest in procuring 5 crore doses from Moderna for 2022 and has requested confirmation from the central government in respect of stability in regulatory requirements/policy regime. The Health Ministry has also been asked to take an early decision on Cipla's request regarding support required by them for procurement of Moderna vaccines.


In the case of Pfizer, the US pharma giant has indicated availability of 5 crore vaccine doses -- 1 crore in July, 1 crore in August, 2 crore in September and 1 crore in October --for supply to India in 2021 and that it will deal only with Government of India and payment for vaccines will have to be made by GOI to Pfizer India.


The central government will make its own arrangement for further channelization of procured vaccines in the domestic market.


According to another source, for the supply of vaccines to India, Pfizer has asked for indemnification from the Government of India and a document in this regard has been received from Pfizer Inc.


Further, Pfizer has also sought certain relaxations in the regulatory regime, including relaxation in the requirement of post-approval bridging trials and dispensing the requirement of testing their vaccines in CDL (Central Drugs Laboratory).


Taking into consideration the track record of the company, similar arrangements done with other countries in the world and the current pandemic situation, an overall view may be taken to indemnify the company by the government, officials said but flagged that in case a view is taken to indemnify the company, similar demands may be made by other companies.


As per the information furnished by Pfizer, around 116 countries in the world including the USA have signed the indemnification document.


Further, considering that over 14.7 crore doses of Pfizer had been administered worldwide without any significant reports of adverse effects, a view needs to be taken to indemnify the company in order to supplement the availability of vaccines in India, officials discussed at one recent meeting.


It was suggested that a decision on the issue of Pfizer Inc may be taken at the earliest and that NEGVAC (National Expert Group on Vaccine Administration for COVID-19) may hold a meeting immediately on these issues.


At a press conference on Monday, in response to a question on states being unable to procure vaccines directly from Moderna and Pfizer, Health Ministry Joint Secretary Lav Agarwal had said,


"Whether it is Pfizer or Moderna, at the Centre-level, we have been coordinating with them."


"Also, the order book of both Pfizer and Moderna is full so it depends on their surplus that how much they can provide in India... they will come back to the Centre and we will help in facilitation to states," he said.
 

Saaho

Senior member
Dec 27, 2019
1,838
1,340
Earth
2 more weeks for EUA application.

So this is why Zycov-D is taking time... They are trying out a two dose regime as well. 10 days for those results to flow in.